Trial Profile
Overall Survival With Ponatinib Versus Allogeneic Stem Cell Transplant in Philadelphia-positive Leukemias With the T315I Mutation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 07 Apr 2017 Results of post hoc indirect comparison of overall survival, published in the Cancer
- 08 Dec 2016 New trial record